• Logo
  • SBMUJournals

Assessment of Clindamycin and Erythromycin Resistance, and Inducible Clindamycin Resistance in Streptococcus Group B Isolated from Urinary Samples of Outpatient Women in Tehran

Homa Frouhesh-Tehrani, Asghar Ashrafi-Hafez, Zohreh Sharifi, Hossein Farahzadi




Background: Streptococcus group B (GBS) or Streptococcus agalactiae is typically associated with neonatal disease and infection in pregnant women. Mortality of GBS sepsis in neonates is over 50% and is particularly high in preterm infants. GBS also causes invasive infection in pregnant and non-pregnant women including urinary tract infection (UTI). Penicillin-derived antibiotics remained as choice drugs for treatment of GBS infection; however, Erythromycin and Clindamycin are useful in cases of allergic to Penicillin. The aim of this study was to investigate the resistance to Erythromycin and Clindamycin, especially inducible Clindamycin resistance, in GBS isolated from urinary samples of women who attended medical offices in Tehran, Iran.

Materials and Methods: This study was conducted on 5000 urine samples from Jan. 2011 to Oct. 2012 that 104 GBS were isolated. The isolates were identified as GBS using laboratory criteria. Antimicrobial susceptibility test was done by Erythromycin disk 15µg and Clindamycin disk 2µg for observation inducible resistant D-zone test by double-disk diffusion method with Erythromycin and adjacent Clindamycin.

Results: Among the 5000 urine samples 104 (2.08%) were Beta hemolytic GBS. Of the 104 isolated GBS, 22 (21.2%) were resistance, 24 (23%) were intermediate, and 58 (55.8%) were susceptible to Erythromycin; however, 24 (23%) were resistance, 5 (4.8%) were intermediate, and 75 (72.2%) were susceptible to Clindamycin. Of the 22 Erythromycin-resistant isolates, 10 (9.5% in total GBS isolated) displayed the D zone; it means they have inducible Erythromycin resistant to Clindamycin.

Conclusion: Various studies in other countries report lower rates of inducible Clindamycin resistance; it indicates the use of more macrolides in the treatment of UTI.


Ulett GC1, Webb RI, Ulett KB, Cui X, Benjamin WH, Crowley M, et al. Group B Streptococcus (GBS) Urinary Tract Infection Involves Binding of GBS to Bladder Uroepithelium and Potent but GBS-Specific Induction of Interleukin 1a. J Infect Dis. 2010;201:866–70

Edwards MS, Baker CJ. Group B streptococcal infections in elderly adults. Clin Infect Dis. 2005;41:839–47.

Atalay A, Ölçü M, Perçin D. Antibiotic Susceptibilities and Serotyping of Clinical Streptococcus Agalactiae Isolates. Balkan Med J. 2011;28:362-5

Rahbar M, Hajia M, Mohammadzadeh M. Urinary Tract Infections Caused By Group B Streptococcus in Adult Women: Survey of 11800 Urine Culture Results. Iranian Journal of Pathology. 2012;7(1):32–7

Clifford V, Heffernan HM, Grimwood K, Garland S. Variation in Erythromycin and Clindamycin resistance patterns between New Zealand and Australian group B streptococcus isolates. Aust N Z J Obstet Gynaecol. 2011;51(4):328-32

Heelan JS, Hasenbein ME, McAdam A J. Resistance of Group B Streptococcus to Selected Antibiotics, Including Erythromycin and Clindamycin. J. Clin. Microbiol. 2004;42(3):1263–4

Schuchat A, Wenger JD. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies and vaccine development. Epidemiol Rev. 1994;16:374-402.

Farley MM. Group B Streptococcal Disease in Nonpregnant Adults. Clin Infect Dis. 2001;33:556–61

Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing, 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.

Acikgoz ZC, Almayanlar E, Gamberzade S, Gocer S. Macrolide Resistance Determinants of Invasive and Noninvasive Group B Streptococci in a Turkish Hospital. AAC. 2004;48(4):1410–2

Raney PM, Tenover FC, Carey RB, McGowan JE Jr, Patel JB. Investigation of inducible Clindamycin and telithromycin resistance in isolates of β-hemolytic streptococci. Diagnostic Microbiology and Infectious Disease. 2006;55:213–8

Borchardt SM, Foxman B, DeBusscher JH, Tallman PA, Manning SD, Marrs CF, et al. Frequency of antimicrobial resistance among invasive and colonizing Group B Streptococcal isolates. BMC Infectious Diseases. 2006;57(6)

Ulett KB, Ulett GC, Benjamin WH Jr, Zhuo F, Xiao M, Kong F, et al. Diversity of Group B Streptococcus Serotypes Causing Urinary Tract Infection in Adults. JCM. 2009;47(7):2055–60

Castor ML, Whitney CG, Como-Sabetti K, Facklam RR, Ferrieri P, Bartkus JM, et al. Antibiotic Resistance Patterns in Invasive Group B Streptococcal Isolates. Infec Dis in Obstetrics and Gynecology 2008.

Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482– 492.

Desjardins D, Delgaty KL, Ramotar K, Seetaram C, Toye B. Prevalence and Mechanisms of Erythromycin Resistance in Group Aand Group B Streptococcus: Implications for Reporting Susceptibility Results. J. Clin. Microbiol. 2004;42(12):5620–3.

Aracil B, Alo´s JI, Minambres M, Oteo J, De La Rosa M, Gomez-Garces JL. Susceptibility of strains of Streptococcus agalactiae to macrolides and lincosamides, phenotype patterns and resistance genes. Clin Microbiol Infect. 2002;8:745–8.

Heelan JS, Hasenbein ME, McAdam A J. Resistance of Group B Streptococcus to Selected Antibiotics, Including Erythromycin and Clindamycin. J Clin Microbiol. 2004;42(3):1263–4

Brzychczy-Włoch M, Gosiewski T, Bodaszewska M, Pabian W, Bulanda M, Kochan P. Genetic characterization and diversity of Streptococcus agalactiae isolates with macrolide resistance. JMM. 2010;59:780–6.

Capraro GA, Rambin ED, Vanchiere JA, Bocchini JA, Matthews-Greer JM. High Rates of Inducible Clindamycin Resistance among Prenatal Group B Streptococcal Isolates in One Northwest Louisiana Academic Medical Center. JCM. 2013;51(7):2469.

DOI: https://doi.org/10.22037/nbm.v3i2.8678